Adverse haematological effects of ticlopidine

Drug Safety

Volumn 19, Issue 2, 1998, Pages 89-98

  Love, Betsy B ^a   Biller, José ^a,c   Gent, Michael ^b  

^a INDIANA UNIVERSITY   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; HEPARIN; NITRATE; TICLOPIDINE;

AGRANULOCYTOSIS; APLASTIC ANEMIA; ARTERY DISEASE; ARTERY THROMBOSIS; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; EARLY DIAGNOSIS; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PANCYTOPENIA; PATIENT EDUCATION; PATIENT MONITORING; PEPTIC ULCER; PLASMAPHERESIS; PRIORITY JOURNAL; RASH; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSTABLE ANGINA PECTORIS;

EID: 0031814242     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199819020-00002     Document Type: Article

References (45)

1. Gent M, Blakeley JA, Easton JD, and the CATS Group. The Canadian-American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1984; 1: 1215-20
2. Hass WK, Easton JD, Adams HP, et al. for the Ticlopidine Aspirin Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients. N Engl J Med 1989; 321: 501-7
3. Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication: effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990; 227: 301-8
4. Balsano F, Rizzon P, Violi F, et al. and the STAI group. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. Circulation 1990; 82: 17-26
5. Schomig A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulation therapy after the placement of coronary-artery-stents. N Engl J Med 1996; 334: 1084-9
6. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106
7. Becquemin J-P, for the Etude de la Ticlopidine Après Pontage Femero-Poplité and the Association Universitaire de Recherche en Chirugie. Effect of ticlopidine on long-term patency of saphenous-vein bypass grafts in the legs. N Engl J Med 1997; 337: 1726-31
8. Saltiel E, Ward A: Ticlopidine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 1987; 34: 222-62
9. Stein B, Fuster V, Israel DH, et al. Platelet inhibitor agents in cardiovascular disease: an update. J Am Coll Cardiol 1989; 813-36
10. Defreyn G, Bernat A, Delebassee D, et al. Pharmacology of ticlopidine: a review. Semin Thromb Hem 1989; 15: 159-66
11. Shah J, Teitelbaum P, Moloby B, et al. Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects. Br J Clin Pharmacol 1991; 32: 761-4
12. Barnett HJM, Eliasziw M, Meldrum HE. Prevention of ischemic stroke [letter]. N Engl J Med 1995; 333: 460
13. Wysowksi DK, Bacsanyi J. Blood dyscrasias and hematologic reactions in ticlopidine users [letter]. JAMA 1996; 276: 952
14. National Disease and Therapeutic Index. Plymouth Meeting PA: IMS America, 1992-1995
15. Quaglino D, Venturoni L, Cretara G, et al. Reversible bone marrow suppression primarily involving granulopoiesis following the use of ticlopidine. Haematologica 1982; 67: 940-1
16. Resegotti L, Pistone MA, Testa D, et al. Bone marrow culture in patients receiving ticlopidine treatment. Nouv Rev Fr Hematol 1985; 27: 19-22
17. Abou-Khalil WH, Lim LO, Yunnis AA, et al. Effects of ticlopidine, a new platelet antiaggregating agent, and its analogues on mitochondrial metabolism, oxidative phosphorylation, protein synthesis and DNA polymerase activity. Biochem Pharmacol 1984; 33: 3893-8
18. Haynes RB, Sandler RS, Larson EB, et al. A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events. Arch Intern Med 1992; 152: 1376-80
19. Haushofer A, Halbmayer WM, Prachar H. Neutropenia with ticlopidine plus aspirin. Lancet 1997; 349: 474-5
20. Onu K, Kurohara K, Yoshihara M, et al. Agranulocytosis caused by ticlopidine and its mechanism. Am J Hematology 1991; 37: 239-42
21. Elias M, Reichman N, Flatau E. Bone marrow aplasia associated with ticlopidine therapy [letter]. Am J Hematol 1993; 44: 289-91
22. Farver DK, Hansen LA. Delayed neutropenia with ticlopidine. Ann Pharmacother 1994; 28: 1344-6
23. Gelatko SM, Melbourne KM, Mikolich DJ. Pseudomonas bacteremia precipitated by ticlopidine-induced neutropenia. Ann Pharmacother 1996; 30: 246-8
24. Johanning RJ, Tschida SJ. Pseudomonas bacteremia secondary to ticlopidine-induced agranulocytosis [letter]. Ann Pharmacother 1996; 30: 1201
25. Carlson JA, Maesner JE. Fatal neutropenia and thrombocytopenia associated with ticlopidine. Ann Pharmacother 1994; 28: 1236-7
26. Ruiz-Irastorza G, Alonso JJ, Iglesias JJ, et al. Granulocyte colony-stimulating factor for neutropenia secondary to ticlopidine. Acta Haematol 1994; 91: 106-7
27. Garnier G, Taillan B, Pesce A, et al. Ticlopidine and severe aplastic anemia [letter]. Br J Haematology 1992; 81: 459-60
28. Troussard X, Mayo P, Mosquet B, et al. Ticlopidine and severe aplastie anemia [letter]. Br J Haematol 1992; 82: 779-80
29. Khelif A, Assouline D, French M, et al. Ticlopidine and aplastic anaemia [letter]. Br J Haematol 1993; 83: 678-81
30. Martin-Nunez G, Fdex-Soria RR, Sanchez-Gil F, et al. Aplastic anemia and ticlopidine [letter]. Br J Haematol 1991; 85: 633-40
31. Lesesve J-F, Callat M-P, Lenormand B, et al. Hematological toxicity of ticlopidine [letter]. Am J Hematol 1994; 47: 149-50
32. Mallet L, Mallet J. Ticlopidine and fatal aplastic anemia in an elderly woman. Ann Pharmacother 1994; 28: 1169-71
33. Rodriguez JN, Fernandez-Jurado A, Dieguez JC, et al. Ticlopidine and severe aplastic anemia [letter]. Am J Hematol 1994; 47: 332
34. Arribalzaga K, Garcia-Suårez, Lopez-Rubio M, et al. Sustained granulocyte recovery after G-CSF in a patient with ticlopidine-induced severe aplastic anemia [letter]. Am J Hematol 1995; 50: 313-20
35. Dunn P. Aplastic anemia with ticlopidine therapy in two Chinese patients [letter]. Ann Pharmacother 1996; 30: 547
36. Shapiro CM, Walk D. Aplastic anemia associated with ticlopidine [letter]. Neurology 1996; 47: 300
37. Yunis AA, Arimura GK, Lo L. Comparative effects of ticlopidine and analogues on in vitro myeloid colony (CGU-GM) growth. Agents and Actions Supplements, Ticlopidine: Quo Vadis? 1984; 15: 136-47
38. Takishita S, Kawazoe N, Yoshida T, et al. Ticlopidine and thrombocytopenia [letter]. N Engl J Med 1990; 323: 1487
39. Capra R, Marciano N, Fieni F, et al. Cerebral hemorrhage and thrombotic thrombocytopenic purpura during ticlopidine treatment: case report. Acta Neurol Belg 1992; 92: 83-7
40. Ariyoshi K, Shinohara K, Ruirong X. Thrombotic thrombocytopenic purpura caused by ticlopidine, successfully treated by plasmapheresis. Am J Hematol 1997; 54: 175-6
41. Falezza G, Girelli D, Olivieri O, et al. Thrombotic thrombocytopenic purpura developed during ticlopidine therapy [letter]. Haematologica 1992; 77: 525
42. Kovacs MJ, Soong PY, Chin-Yee IH. Thrombotic thrombocytopenic purpura associated with ticlopidine. Ann Pharmacother 1993; 27: 1060-1
43. Page Y, Tardy B, Zeni F, et al. Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet 1991; 337: 774-6
44. Ellie E, Durrieu C, Besse P, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. Stroke 1992; 23: 922-3
45. Piscotto P. Treatment of thrombocytopenic purpura: evaluation of plasma exchange and review of the literature. Vox Sang 1983; 45: 185-96